{"id":33090,"date":"2020-10-15T16:18:05","date_gmt":"2020-10-15T14:18:05","guid":{"rendered":"https:\/\/www.embl.org\/news\/?p=33090"},"modified":"2025-07-15T12:43:02","modified_gmt":"2025-07-15T10:43:02","slug":"repurposing-drugs-for-coronaviruses","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/","title":{"rendered":"Repurposing drugs for a pan-coronavirus treatment"},"content":{"rendered":"\n

A large international consortium of almost 200 researchers from 14 leading institutions in six countries has studied three different coronaviruses \u2013 SARS-CoV-1, SARS-CoV-2, and MERS-CoV \u2013 with the aim of finding vulnerabilities shared by these three pathogens. The research, published in the journal Science<\/em><\/a>, identifies important molecular mechanisms crucial for all three coronaviruses, as well as potential drugs that could be repurposed as pan-coronavirus treatments.\u00a0<\/p>\n\n\n\n

The consortium included researchers at EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), the Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG) at University of California San Francisco (UCSF), Gladstone Institutes, Institut Pasteur, Cluster of Excellence CIBSS at the University of Freiburg, the Howard Hughes Medical Institute, and other collaborators including the biotechnology companies Aetion<\/a> and Synthego<\/a>.<\/p>\n\n\n\n

There are three known human respiratory syndromes associated with coronaviruses: severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19). These are caused by SARS-CoV-1, MERS-CoV, and SARS-CoV-2, respectively. <\/p>\n\n\n\n

The scientists identified drug targets and repurposed therapeutics that may have broad-spectrum activity across all three coronavirus strains. Repurposed therapeutics with known safety profiles may offer a rapid treatment response against emerging coronavirus strains in the future.<\/p>\n\n\n\n

Identifying coronavirus drug targets<\/strong><\/h3>\n\n\n\n

Building on their previous work published in Nature<\/em><\/a> and Cell<\/em><\/a>, the scientists determined how viral and human proteins interact, and where viral proteins are located within host cells infected by different coronaviruses. They subsequently used this data and functional genetic screening to identify host factors that prevent coronavirus propagation. The data analysed in this study will be made freely accessible through the COVID-19 Data Portal<\/a>. <\/p>\n\n\n\n

\u201cThese analyses demonstrate how biological and molecular information are translated into real-world implications for the treatment of COVID-19 and other viral diseases,\u201d says Pedro Beltrao, Group Leader at EMBL-EBI<\/a>. \u201cAfter more than a century of relatively harmless coronaviruses, in the last 20 years we\u2019ve had three coronaviruses that have been deadly. By looking across the species, we have the capability to predict pan-coronavirus therapeutics that may be effective in treating the current pandemic, which we believe will also offer promising therapeutics for a future coronavirus as well.\u201d<\/p>\n\n\n\n

Another step to treat COVID-19<\/strong><\/h3>\n\n\n\n

The researchers also performed real-world analysis on clinical data regarding COVID-19 patient outcomes. To do this, they identified molecules in human cells that could be targeted with FDA-approved therapeutics and looked to see what effect these drugs had on COVID-19 patients in the clinic. This analysis involved over 740 000 patients in the United States with known SARS-CoV-2 infection.<\/p>\n\n\n\n

The data and analysis carried out in this study demonstrate how molecular information can be translated into real-world implications for the treatment of COVID-19. This study also showcases a collaborative approach that can be applied to study other infectious agents in the future. \u201cThis far-reaching international study elucidates for the first time commonalities and, importantly, vulnerabilities, across coronaviruses, including our current challenge with the COVID-19 pandemic,\u201d says Nevan Krogan, Director of QBI and Senior Investigator at Gladstone Institutes<\/a>. \u201cIn unique and rapid fashion, we were able to bridge biological and functional insights with clinical outcomes, providing an exemplary model of a differentiated way to conduct research into any disease, rapidly identify promising treatments and advance knowledge in the fields of both science and medicine. This body of work was only made possible through the collaborative efforts of senior scientific thought leaders and the teams of next-generation researchers at premier institutions across the globe.\u201d<\/p>\n\n\n\n

\n\n\n\n

Reposicionan f\u00e1rmacos existentes para tratar los coronavirus<\/h1>\n\n\n\n

Dianas farmacol\u00f3gicas comunes en tres cepas distintas de coronavirus se podr\u00edan utilizar en el futuro como tratamiento de respuesta r\u00e1pida contra nuevas cepas emergentes de este tipo de virus<\/h3>\n\n\n\n

Un consorcio internacional de casi 200 investigadores, entre ellos varios espa\u00f1oles, de 14 instituciones l\u00edderes en cinco pa\u00edses, ha estudiado tres coronavirus diferentes: el SARS-CoV-1, el SARS-CoV-2 y el MERS-CoV, con el objetivo de encontrar vulnerabilidades compartidas por estos tres pat\u00f3genos. La investigaci\u00f3n, publicada en la revista Science<\/em><\/a>, identifica mecanismos moleculares cruciales para los tres coronavirus, as\u00ed como medicamentos existentes que potencialmente podr\u00edan reutilizarse como tratamientos para los coronavirus.<\/p>\n\n\n\n

Entre los cient\u00edficos que colaboraron a la investigaci\u00f3n se encuentra personal del Instituto Europeo de Bioinform\u00e1tica del EMBL (EMBL-EBI) \u2013un centro tambi\u00e9n con sede en Barcelona\u2013, el Grupo de Investigaci\u00f3n de Coronavirus del Instituto de Biociencias Cuantitativas (QBI) (QCRG) de la Universidad de California en San Francisco (UCSF), los Institutos Gladstone, el Instituto Pasteur, el Grupo de Excelencia CIBSS de la Universidad de Freiburg, el Instituto M\u00e9dico Howard Hughes y otros colaboradores, incluidas las empresas de biotecnolog\u00eda Aetion<\/a> y Synthego<\/a>.<\/p>\n\n\n\n

Hay tres s\u00edndromes respiratorios humanos conocidos que son asociados con los coronavirus: el s\u00edndrome respiratorio agudo severo (SARS), causado por el SARS-CoV-1; el s\u00edndrome respiratorio de Oriente Medio (MERS), causado por el MERS-CoV; y la COVID-19, causada \u200b\u200bpor el SARS-CoV-2.<\/p>\n\n\n\n

Los autores del nuevo estudio han podido identificar objetivos farmacol\u00f3gicos contra estos virus, y han identificado terapias existentes que pueden tener una actividad de amplio espectro para todas las tres cepas de coronavirus. El hecho de que se trate de terapias ya utilizadas y \u201creposicionadas\u201d, como se dice en estos casos, hace que tengan perfiles de seguridad ya conocidos, y a la vez que puedan constituir un tratamiento de respuesta r\u00e1pida contra cepas emergentes de nuevos coronavirus.<\/p>\n\n\n\n

Objetivos farmacol\u00f3gicos contra los coronavirus<\/strong><\/h3>\n\n\n\n

Bas\u00e1ndose en su trabajo previamente publicado en Nature<\/em><\/a> y Cell<\/em><\/a>, los cient\u00edficos han determinado c\u00f3mo interact\u00faan las prote\u00ednas virales y las humanas, y d\u00f3nde se encuentran las prote\u00ednas virales en las c\u00e9lulas hu\u00e9sped infectadas por diferentes coronavirus. A continuaci\u00f3n, han utilizado estos datos y el cribado gen\u00e9tico funcional para identificar los factores del hu\u00e9sped que previenen la propagaci\u00f3n del coronavirus. Los datos analizados en este estudio ser\u00e1n de libre acceso a trav\u00e9s del Portal de datos COVID-19<\/a>.<\/p>\n\n\n\n

\u201cNuestra investigaci\u00f3n demuestra c\u00f3mo la informaci\u00f3n biol\u00f3gica y molecular se traduce directamente en herramientas concretas para el tratamiento de la COVID-19 y de otras enfermedades virales\u201d, afirma Pedro Beltrao, jefe de grupo en el EMBL-EBI y uno de los autores del estudio. \u201cDespu\u00e9s de m\u00e1s de un siglo en el que los coronavirus han sido relativamente inofensivos, en los \u00faltimos 20 a\u00f1os nos hemos encontrado con tres coronavirus que han sido mortales. Observando las tres cepas, hemos sido capaces de predecir una terapia apta para los tres coronavirus que creemos podr\u00eda tambi\u00e9n ser eficaz en el tratamiento de la actual pandemia, as\u00ed como ofrecer terapias prometedoras para un eventual nuevo coronavirus\u201d.<\/p>\n\n\n\n

Un paso hacia el tratamiento de la COVID-19<\/strong><\/h3>\n\n\n\n

Los investigadores tambi\u00e9n han realizado un paso ulterior analizando datos de los resultados cl\u00ednicos de pacientes con COVID-19. Para hacer esto, han identificado mol\u00e9culas en c\u00e9lulas humanas que pod\u00edan ser dianas de terapias aprobadas por la FDA (la Administraci\u00f3n de Medicamentos y Alimentos estadounidense, por sus siglas inglesas) y han observado qu\u00e9 efecto ten\u00edan estos medicamentos en los pacientes con COVID-19 en la cl\u00ednica. Este an\u00e1lisis ha involucrado a m\u00e1s de 740 000 pacientes en los Estados Unidos con una infecci\u00f3n por SARS-CoV-2 diagnosticada.<\/p>\n\n\n\n

Adem\u00e1s de demostrar c\u00f3mo la investigaci\u00f3n a nivel molecular se puede convertir en herramientas poderosas para la pr\u00e1ctica cl\u00ednica en la lucha contra la COVID-19, los datos y el an\u00e1lisis llevados a cabo en este estudio ponen de relieve la importancia de un enfoque colaborativo que se puede aplicar para estudiar otros agentes infecciosos en el futuro. \u201cEste estudio internacional de gran alcance aclara por primera vez las propiedades en com\u00fan y, sobre todo, las vulnerabilidades de los coronavirus, incluido el que representa el desaf\u00edo m\u00e1s actual, el causante de la pandemia de COVID-19\u201d, dice Nevan Krogan, director del QBI e investigador principal de los Institutos Gladstone<\/a>. \u201cDe una manera \u00fanica y r\u00e1pida, hemos sido capaces de unir los conocimientos biol\u00f3gicos y funcionales con los resultados cl\u00ednicos, proporcionando un modelo ejemplar de una manera diferenciada para realizar investigaciones sobre cualquier enfermedad, identificar r\u00e1pidamente tratamientos prometedores y avanzar en el conocimiento en la ciencia y en la medicina. Todo esto solo ha sido posible gracias a los esfuerzos colaborativos de l\u00edderes cient\u00edficos de primer nivel, y de equipos de investigadores de pr\u00f3xima generaci\u00f3n en instituciones cient\u00edficas punteras en todo el mundo\u201d.<\/p>\n\n\n\n

\n\n\n\n

Riposizionare i farmaci per una cura contro i coronavirus<\/h1>\n\n\n\n

I bersagli farmaceutici comuni a tre ceppi di coronavirus potrebbero essere utilizzati per trattamenti a risposta rapida contro ceppi di coronavirus emergenti<\/h3>\n\n\n\n

Un consorzio internazionale di quasi 200 ricercatori provenienti da 14 importanti istituzioni di sei paesi, tra cui l\u2019Italia, ha studiato tre diversi coronavirus – SARS-CoV-1, SARS-CoV-2 e MERS-CoV – con l’obiettivo di trovare le vulnerabilit\u00e0 comuni a questi tre patogeni. La ricerca, pubblicata sulla rivista Science<\/em>, identifica importanti meccanismi molecolari cruciali per tutti e tre i coronavirus, ed individua potenziali farmaci che potrebbero essere riconvertiti come trattamenti validi per tutti i coronavirus.<\/p>\n\n\n\n

Il consorzio comprende ricercatori dell’European Bioinformatics Institute dell’EMBL (EMBL-EBI) \u2013 un  centro, l\u2019EMBL, che possiede una sede anche a Roma \u2013, del Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG) dell’Universit\u00e0 della California San Francisco (UCSF), dei Gladstone Institutes, dell\u2019Institut Pasteur, del Cluster of Excellence CIBSS dell’Universit\u00e0 di Friburgo, dell’Howard Hughes Medical Institute, e altri collaboratori, tra cui le aziende biotecnologiche Aetion e Synthego.<\/p>\n\n\n\n

Attualmente sono note tre sindromi respiratorie umane associate ai coronavirus: la sindrome respiratoria acuta grave (SARS), la sindrome respiratoria del Medio Oriente (MERS) e la COVID-19. Queste sono causate rispettivamente dal SARS-CoV-1, dal MERS-CoV e dal SARS-CoV-2.<\/p>\n\n\n\n

I ricercatori hanno identificato bersagli farmaceutici e utilizzato terapie \u201crepurposed\u201d, cio\u00e8 farmaci esistenti che vengono \u201criposizionati\u201d, che potrebbero avere attivit\u00e0 ad ampio spettro sui tre ceppi di coronavirus.<\/p>\n\n\n\n

Queste terapie riadattate \u2013 avendo profili di sicurezza gi\u00e0 noti \u2013 possono offrire una risposta rapida al trattamento contro i futuri ceppi di coronavirus emergenti.<\/p>\n\n\n\n

Identificare i bersagli dei farmaci contro il coronavirus<\/strong><\/h3>\n\n\n\n

Sulla base dei loro precedenti lavori pubblicati su Nature<\/em> e Cell<\/em>, gli scienziati hanno studiato l\u2019interazione tra le proteine virali e quelle umane e la localizzazione delle proteine virali nelle cellule ospiti infettate da diversi coronavirus. Successivamente, hanno utilizzato questi dati e lo screening genetico funzionale per identificare i fattori dell’ospite che impediscono la propagazione del coronavirus. I dati analizzati in questo studio saranno resi disponibili in accesso libero attraverso il Portale Dati COVID-19.<\/p>\n\n\n\n

“Queste analisi dimostrano come le informazioni biologiche e molecolari si traducono in strumenti concreti per il trattamento di COVID-19 e di altre malattie virali”, afferma Pedro Beltrao, Group Leader di EMBL-EBI. “Dopo pi\u00f9 di un secolo di coronavirus relativamente innocui, negli ultimi 20 anni abbiamo avuto tre coronavirus che sono stati mortali. Guardando tra le specie, abbiamo la capacit\u00e0 di anticipare una terapia contro i coronavirus che non solo pu\u00f2 essere efficace nel trattamento dell\u2019attuale pandemia, ma anche offrire nel futuro terapie promettenti nei confronti di eventuali nuovi coronavirus.\u201d<\/p>\n\n\n\n

Un passo verso il trattamento del COVID-19<\/strong><\/h3>\n\n\n\n

I ricercatori hanno anche eseguito analisi su dati clinici reali relativi ai risultati su pazienti COVID-19. A questo scopo, hanno identificato nelle cellule umane quelle molecole che potrebbero essere bersaglio di terapie approvata dalla FDA statunitense, e hanno osservato gli effetti che questi farmaci avevano sul decorso clinico dei pazienti COVID-19. L\u2019analisi ha coinvolto oltre 740 000 pazienti positivi all\u2019infezione da SARS-CoV-2 negli Stati Uniti.<\/p>\n\n\n\n

I dati e le analisi effettuate in questo studio dimostrano come le informazioni molecolari possano essere tradotte in implicazioni reali per il trattamento di COVID-19. Questo studio mostra anche un approccio collaborativo che potr\u00e0 essere applicato anche per studiare altri agenti infettivi in futuro.<\/p>\n\n\n\n

“Questo studio internazionale di ampia portata chiarisce per la prima volta le caratteristiche e soprattutto le vulnerabilit\u00e0 comuni ai vari ceppi di coronavirus”, dice Nevan Krogan, Direttore del QBI e Senior Investigator dei Gladstone Institutes. “In modo unico e rapido, siamo stati in grado di collegare le evidenze biologiche e funzionali con i risultati clinici, fornendo un modello esemplare di conduzione di una ricerca su qualsiasi malattia, identificazione rapida di cure promettenti e di progresso delle conoscenze nel campo della scienza e della medicina”. Questo lavoro \u00e8 stato reso possibile solo grazie agli sforzi collaborativi dei leader scientifici e dei team di ricercatori della prossima generazione presso le pi\u00f9 importanti istituzioni di ricerca di tutto il mondo”.<\/p>\n","protected":false},"excerpt":{"rendered":"

Scientists from the Beltrao Group at EMBL-EBI and collaborators identified drug targets common to SARS-CoV-2, SARS-CoV-1, and MERS-CoV, three pathogenic coronaviruses. They also found potential drugs that could be repurposed as COVID-19 treatments, and against emerging coronavirus strains in the…<\/p>\n","protected":false},"author":77,"featured_media":33094,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2,17591],"tags":[442,28,297,1025,1331,312,36,1329],"embl_taxonomy":[10042,2906],"class_list":["post-33090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science","category-science-technology","tag-beltrao","tag-bioinformatics","tag-biomedical","tag-coronavirus","tag-covid-19","tag-drug-discovery","tag-embl-ebi","tag-sars-cov-2","embl_taxonomy-beltrao-group","embl_taxonomy-embl-ebi"],"acf":{"featured":true,"show_featured_image":false,"color":"#193f90","link_color":"#fff","article_intro":"

Drug targets common across three coronavirus strains could be used for rapid treatment response against emerging coronavirus strains<\/p>\n","related_links":[{"link_description":"New findings on SARS-CoV-2 protein shed light on virus\u2019s ability to infect cells","link_url":"https:\/\/www.embl.org\/news\/science\/flexible-corona\/"},{"link_description":"Existing drugs can prevent SARS-CoV-2 from hijacking cells","link_url":"https:\/\/www.embl.org\/news\/science\/existing-drugs-can-prevent-sars-cov-2-from-highjacking-cells\/"},{"link_description":"Silencing the SARS-CoV-2 receptor with epigenetic modifications","link_url":"https:\/\/www.embl.org\/news\/science\/silencing-the-sars-cov-2-receptor-with-epigenetic-modifications\/"}],"article_sources":[{"source_description":"

Gordon, DE, et al<\/em>. (2020). Comparative Host-Coronavirus Protein Interaction Networks Reveal Pan-Viral Disease Mechanisms.<\/a> Science,<\/i> published online 15 October; DOI: 10.1126\/science.abe9403<\/p>\n","source_link_url":""}],"in_this_article":false,"youtube_url":"","mp4_url":"","video_caption":"","press_contact":"EMBL-EBI Generic","translations":[{"translation_language":"Spanish","translation_anchor":"#a1"},{"translation_language":"Italian","translation_anchor":"#a2"}],"vf_locked":false},"embl_taxonomy_terms":[{"uuid":"a:3:{i:0;s:36:\"302cfdf7-365b-462a-be65-82c7b783ebf7\";i:1;s:36:\"442a4893-2c31-4523-b9eb-fb1ee4bd2037\";i:2;s:36:\"3d361176-0d12-49ff-9327-3f51a4a6da83\";}","parents":[],"name":["Beltrao Group"],"slug":"beltrao-group","description":"What > EMBL-EBI Research > Beltrao Group"},{"uuid":"a:3:{i:0;s:36:\"b14d3f13-5670-44fb-8970-e54dfd9c921a\";i:1;s:36:\"89e00fee-87f4-482e-a801-4c3548bb6a58\";i:2;s:36:\"a99d1a7c-ca83-4c00-ab61-d082d3e41ce3\";}","parents":[],"name":["EMBL-EBI"],"slug":"embl-ebi","description":"Where > All EMBL sites > EMBL-EBI"}],"yoast_head":"\nRepurposing drugs for a pan-coronavirus treatment | EMBL<\/title>\n<meta name=\"description\" content=\"Scientists identified drug targets common to SARS-CoV-2, SARS-CoV-1, and MERS-CoV, and potential drugs for COVID-19 treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Repurposing drugs for a pan-coronavirus treatment | EMBL\" \/>\n<meta property=\"og:description\" content=\"Scientists identified drug targets common to SARS-CoV-2, SARS-CoV-1, and MERS-CoV, and potential drugs for COVID-19 treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-15T14:18:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-15T10:43:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Vicky Hatch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Vicky Hatch\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/\"},\"author\":{\"name\":\"Vicky Hatch\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/d8477ba2d7a6164b141a3872a25ee982\"},\"headline\":\"Repurposing drugs for a pan-coronavirus treatment\",\"datePublished\":\"2020-10-15T14:18:05+00:00\",\"dateModified\":\"2025-07-15T10:43:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/\"},\"wordCount\":2080,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg\",\"keywords\":[\"beltrao\",\"bioinformatics\",\"biomedical\",\"coronavirus\",\"covid-19\",\"drug discovery\",\"embl-ebi\",\"sars-cov-2\"],\"articleSection\":[\"Science\",\"Science & Technology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/\",\"url\":\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/\",\"name\":\"Repurposing drugs for a pan-coronavirus treatment | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg\",\"datePublished\":\"2020-10-15T14:18:05+00:00\",\"dateModified\":\"2025-07-15T10:43:02+00:00\",\"description\":\"Scientists identified drug targets common to SARS-CoV-2, SARS-CoV-1, and MERS-CoV, and potential drugs for COVID-19 treatment.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg\",\"width\":1000,\"height\":600,\"caption\":\"Interacting human proteins (Tom70, shown in green), and coronavirus proteins (Orf9b, shown in pink), in colon epithelial cells. Cell nuclei are shown in cyan. Image: Svenja Ulferts\/University of Freiburg. Design credit: Spencer Phillips\/EMBL-EBI.\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/d8477ba2d7a6164b141a3872a25ee982\",\"name\":\"Vicky Hatch\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6d864d58088d9e60f42c501aa30714d303efc1ca5aed268210905409910b90d5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6d864d58088d9e60f42c501aa30714d303efc1ca5aed268210905409910b90d5?s=96&d=mm&r=g\",\"caption\":\"Vicky Hatch\"},\"url\":\"https:\/\/www.embl.org\/news\/author\/vicky-hatch-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2--2\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Repurposing drugs for a pan-coronavirus treatment | EMBL","description":"Scientists identified drug targets common to SARS-CoV-2, SARS-CoV-1, and MERS-CoV, and potential drugs for COVID-19 treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/","og_locale":"en_US","og_type":"article","og_title":"Repurposing drugs for a pan-coronavirus treatment | EMBL","og_description":"Scientists identified drug targets common to SARS-CoV-2, SARS-CoV-1, and MERS-CoV, and potential drugs for COVID-19 treatment.","og_url":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2020-10-15T14:18:05+00:00","article_modified_time":"2025-07-15T10:43:02+00:00","og_image":[{"width":1000,"height":600,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg","type":"image\/jpeg"}],"author":"Vicky Hatch","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Vicky Hatch","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/"},"author":{"name":"Vicky Hatch","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/d8477ba2d7a6164b141a3872a25ee982"},"headline":"Repurposing drugs for a pan-coronavirus treatment","datePublished":"2020-10-15T14:18:05+00:00","dateModified":"2025-07-15T10:43:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/"},"wordCount":2080,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg","keywords":["beltrao","bioinformatics","biomedical","coronavirus","covid-19","drug discovery","embl-ebi","sars-cov-2"],"articleSection":["Science","Science & Technology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/","url":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/","name":"Repurposing drugs for a pan-coronavirus treatment | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg","datePublished":"2020-10-15T14:18:05+00:00","dateModified":"2025-07-15T10:43:02+00:00","description":"Scientists identified drug targets common to SARS-CoV-2, SARS-CoV-1, and MERS-CoV, and potential drugs for COVID-19 treatment.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/science\/repurposing-drugs-for-coronaviruses\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg","width":1000,"height":600,"caption":"Interacting human proteins (Tom70, shown in green), and coronavirus proteins (Orf9b, shown in pink), in colon epithelial cells. Cell nuclei are shown in cyan. Image: Svenja Ulferts\/University of Freiburg. Design credit: Spencer Phillips\/EMBL-EBI."},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/d8477ba2d7a6164b141a3872a25ee982","name":"Vicky Hatch","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6d864d58088d9e60f42c501aa30714d303efc1ca5aed268210905409910b90d5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6d864d58088d9e60f42c501aa30714d303efc1ca5aed268210905409910b90d5?s=96&d=mm&r=g","caption":"Vicky Hatch"},"url":"https:\/\/www.embl.org\/news\/author\/vicky-hatch-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2--2\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2020\/10\/BELTRAO-Science2020-Pan-coronavirus_treatments_1000x600.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/33090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/77"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=33090"}],"version-history":[{"count":31,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/33090\/revisions"}],"predecessor-version":[{"id":67155,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/33090\/revisions\/67155"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/33094"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=33090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=33090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=33090"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=33090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}